Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis.
Almasri Malaz, Ismaiel Abdulrahman, Gavris Iulia, Leucuta Daniel-Corneliu, Gavris Monica M, Nicoara Simona Delia
AI Summary
This study found Bromfenac improved visual acuity and Nepafenac 0.3% best prevented macular thickening after cataract surgery, guiding optimal NSAID selection for patient outcomes.
Abstract
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration's tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
MeSH Terms
Shields Classification
Key Concepts5
Bromfenac was associated with a statistically significant better visual acuity compared to Nepafenac 0.1% at one-month post-surgery (p < 0.001) in a network meta-analysis of 11 Randomized Controlled Trials including 2175 subjects comparing different topical NSAIDs after phacoemulsification.
Nepafenac 0.3% had the least increase in foveal thickness compared to Nepafenac 0.1% (p = 0.09) at one-month post-surgery in a network meta-analysis of 11 Randomized Controlled Trials including 2175 subjects comparing different topical NSAIDs after phacoemulsification.
Diclofenac had the lowest intraocular pressure (IOP) at one-month post-surgery in a network meta-analysis of 11 Randomized Controlled Trials including 2175 subjects comparing different topical NSAIDs after phacoemulsification, although no significant results were found regarding IOP overall.
Ketorolac had the worst results regarding best-corrected visual acuity (BCVA) and intraocular pressure (IOP), and came last but one for foveal thickness (FT), at one-month post-surgery in a network meta-analysis of 11 Randomized Controlled Trials including 2175 subjects comparing different topical NSAIDs after phacoemulsification.
A network meta-analysis of 11 Randomized Controlled Trials including 2175 subjects compared the efficacy of different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing macular thickening and their impact on visual acuity and intraocular pressure after phacoemulsification.
Related Articles5
Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial.
Randomized Controlled TrialTopical anti-glaucoma medications effects on meibomian glands: Systematic review and meta-analysis.
Systematic ReviewImproving Glaucoma Patients' Quality of Life and Adherence With a Digital Health Application: [RETRACTED].
Randomized Controlled TrialAnthocyanin oligomer (grape skin extract) administration improves dry eye disease: A randomised, double-blind, placebo-controlled study.
Randomized Controlled TrialAcceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.